Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742796 | 1.00 | CTSK (0.54) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL16119292 | 0.97 | CTSK (0.57) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL3611757 | 0.96 | CTSK (0.59) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL25348435 | 0.96 | CTSK (0.59) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL3611760 | 0.96 | CTSK (0.59) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL27076688 | 0.95 | CTSK (0.56) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL9102937 | 0.95 | CTSK (0.56) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL7856949 | 0.88 | CTSK (0.57) | CTSKCTSSAAK1CACNA1BHDAC4 | |
| SCHEMBL18327535 | 0.88 | BTK (0.44) | CTSKCTSSAAK1JAK3BTK | |
| SCHEMBL18325176 | 0.88 | BTK (0.44) | CTSKCTSSAAK1JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | claimed |
| EP-1919478-B1 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-1891089-B1 | HCV protease inhibitors in combination with food | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005113581-A1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005107745-A1 | AN INHIBITOR OF HEPATITIS C | SCHERING CORPORATION (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005087725-A2 | NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087721-A2 | COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005085197-A1 | CYCLOBUTENEDIONE GROUPS-CONTAINING COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |